Hinge Health (NYSE:HNGE) Stock Price Target Raised at Morgan Stanley

Key Points

• Morgan Stanley raised Hinge Health’s price target from $117 to $131 and maintained an “overweight” rating, implying 12.79% upside from the prior close. The broader analyst consensus is “Moderate Buy,” with an average target of $118.93.
• Hinge Health reported strong quarterly results, earning $0.71 per share versus the $0.27 consensus estimate, while revenue rose 52.4% year over year to $234.97 million. Its fourth-quarter and full-year 2026 revenue guidance also exceeded analyst expectations.
• The stock traded near its 52-week high at $116.14, supported by recent analyst upgrades but carrying a high valuation with a P/E ratio of 90.73. Insiders sold more than 1 million shares worth approximately $95.6 million over the past 90 days.

Hinge Health (NYSE:HNGE - Get Free Report) had its price target upped by analysts at Morgan Stanley from $117.00 to $131.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Morgan Stanley's price objective suggests a potential upside of 12.79% from the stock's previous close.

HNGE has been the subject of a number of other research reports. Wells Fargo & Company upped their price target on Hinge Health from $103.00 to $132.00 and gave the company an "overweight" rating in a research report on Tuesday. Needham & Company LLC lifted their price objective on Hinge Health from $115.00 to $135.00 and gave the stock a "buy" rating in a research report on Tuesday. Weiss Ratings cut Hinge Health from a "hold (c)" rating to a "hold (c-)" rating in a research note on Thursday, October 8th. Citizens Jmp upped their target price on Hinge Health from $96.00 to $107.00 and gave the company a "market outperform" rating in a report on Wednesday, August 5th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Hinge Health in a research note on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $118.93.

Hinge Health Price Performance

NYSE HNGE traded up $0.66 during trading on Tuesday, reaching $116.14. The company's stock had a trading volume of 1,479,849 shares, compared to its average volume of 1,624,486. The stock has a market capitalization of $9.37 billion, a PE ratio of 90.73 and a beta of 1.37. The firm has a fifty day moving average of $98.66 and a 200 day moving average of $67.35. Hinge Health has a one year low of $30.08 and a one year high of $118.86.

Hinge Health (NYSE:HNGE - Get Free Report) last announced its earnings results on Monday, November 2nd. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.44. The company had revenue of $234.97 million during the quarter. Hinge Health had a net margin of 15.15% and a return on equity of 51.60%. The firm's revenue was up 52.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.02) earnings per share. Research analysts expect that Hinge Health will post 1.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO James Budge sold 47,720 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $103.13, for a total value of $4,921,363.60. Following the sale, the chief financial officer directly owned 296,728 shares of the company's stock, valued at approximately $30,601,558.64. This represents a 13.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Perez sold 4,100 shares of the firm's stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $100.20, for a total value of $410,820.00. Following the transaction, the chief executive officer owned 4,100 shares of the company's stock, valued at $410,820. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,024,581 shares of company stock valued at $95,632,761. 18.92% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. 11.2 Capital Management LLC bought a new stake in Hinge Health during the second quarter valued at approximately $204,566,531. Assenagon Asset Management S.A. increased its holdings in Hinge Health by 2,141.9% during the third quarter. Assenagon Asset Management S.A. now owns 1,854,922 shares of the company's stock valued at $180,373,000 after buying an additional 1,772,182 shares during the last quarter. Wellington Management Group LLP increased its holdings in Hinge Health by 169.7% during the second quarter. Wellington Management Group LLP now owns 1,205,584 shares of the company's stock valued at $100,063,000 after buying an additional 758,594 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in Hinge Health by 225.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,163,187 shares of the company's stock worth $44,852,000 after acquiring an additional 806,007 shares during the period. Finally, Estuary Capital Management LP purchased a new position in shares of Hinge Health during the 1st quarter worth $15,201,000.

More Hinge Health News

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q3 results exceeded expectations: Hinge Health reported earnings of $0.71 per share versus consensus estimates of $0.27 and revenue of $234.97 million, up 52.4% year over year. The company also posted a 15.15% net margin and 51.6% return on equity. Hinge Health quarterly earnings report
• Positive Sentiment: Revenue outlook was raised above consensus: Hinge Health guided fourth-quarter 2026 revenue to $249 million-$251 million, compared with the $239.2 million consensus estimate. Full-year revenue guidance of $879 million-$881 million also exceeded the $858.5 million consensus. Hinge Health revenue outlook
• Positive Sentiment: Analysts raised price targets: RBC lifted its target to $135 and maintained an “outperform” rating; Canaccord raised its target to $134 with a “buy” rating; and Stifel increased its target to $135, also retaining a “buy” rating. These targets imply roughly 16% upside from recent trading levels.
• Neutral Sentiment: Management highlighted continued expansion of its technology-enabled care platform and is targeting an integrated gastrointestinal program in summer 2027, providing a potential longer-term growth catalyst.
• Negative Sentiment: The earnings beat may have been largely anticipated, and some coverage indicated results missed the higher “whisper” expectations. With HNGE trading near its 52-week high and at a high valuation, investors may be taking profits despite the favorable fundamental update. Hinge Health earnings expectations analysis

About Hinge Health

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care programs designed to help members manage pain, improve mobility and reduce the need for more costly or invasive treatments.

Its platform combines personalized exercise therapy, behavioral support, education and access to clinical professionals. Hinge Health also uses technologies such as motion-sensing wearable devices and artificial intelligence to help guide exercises, monitor progress and tailor care plans to individual needs.

Hinge Health primarily serves employers and health plans, which offer its programs to eligible members in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.